Changes in the Brain as Borderline Patients Learn to Regulate Their Emotions
Launched by ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · Jun 4, 2015
Trial Information
Current as of August 14, 2025
Completed
Keywords
ClinConnect Summary
Borderline Personality Disorder (BPD) is a common psychiatric disorder found in approximately 2% to 6% of the population . It is characterized by intense and rapid mood changes, self-destructive behavior, suicidality, and tumultuous relationships. In additional to the emotional costs of the suffering experienced by borderline patients and their loved ones, BPD patients typically function at a level substantially below that of individuals with comparable intellect. The difficulty controlling emotion, so central to the disorder, has proved a particularly difficult to treat. The present study ...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • BPD subjects 18 to 50 years old
- • Meet criteria for DSM-IV Borderline Personality Disorder, including the DSM-IV criteria for affective instability (criterion #6), and not meet criteria for Schizotypal Personality Disorder (SPD) or AvPD.
- • Subjects in the AvPD group meet DSM-IV criteria for AvPD and not for BPD or SPD.
- • All subjects will be free of psychotropic medications for 2 weeks (6 weeks for fluoxetine).
- • Subjects may be enrolled in psychotherapy
- Exclusion Criteria:
- • BPD and AvPD subjects will not meet DSM-IV criteria for past or present PTSD, bipolar I disorder, schizophrenia, schizoaffective disorder, substance dependence, head trauma, CNS neurological disease, seizure disorder or current major depression.
- • Substance abuse disorder in the prior 6 months
- • Significant medical illness
- • Pregnancy
- • Metallic foreign-bodies that contraindicate MRI
About Icahn School Of Medicine At Mount Sinai
The Icahn School of Medicine at Mount Sinai is a premier academic institution located in New York City, renowned for its commitment to advancing medical research, education, and patient care. As a leading sponsor of clinical trials, the institution leverages its state-of-the-art facilities and multidisciplinary expertise to drive innovative research initiatives aimed at improving health outcomes. With a focus on translational medicine, the Icahn School of Medicine collaborates with a diverse network of researchers, clinicians, and industry partners to explore novel therapies and interventions across a wide range of medical disciplines. Its rigorous scientific approach and dedication to ethical standards position it as a trusted leader in the clinical research landscape.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
New York, New York, United States
Patients applied
Trial Officials
Harold W Koenigsberg, MD
Principal Investigator
Icahn School of Medicine at Mount Sinai
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials